Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 19 to 23, 2020. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 19 to 23, 2020. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
FRIDAY, Oct. 23, 2020 (HealthDay News) — At a meeting of the U.S. Food and Drug Administration vaccine advisory board, some experts warned that the guidelines requiring two months of safety data after a volunteer has been vaccinated were not enough, TheNew York Timesreported Thursday.
CDC Plans Cellphone COVID-19 Vaccine Tracking System
FRIDAY, Oct. 23, 2020 (HealthDay News) — When a COVID-19 vaccine becomes available, the U.S. Centers for Disease Control and Prevention will monitor those taking the vaccine for any health problems via text messages and online surveys,CNNreported Thursday.
Convalescent Plasma Has Limited Benefit for Moderate COVID-19
FRIDAY, Oct. 23, 2020 (HealthDay News) — For patients with moderate COVID-19, convalescent plasma does not reduce progression to severe COVID-19 or mortality, according to a study published online Oct. 22 in The BMJ.
Survival From COVID-19 High in Patients With Psoriasis
FRIDAY, Oct. 23, 2020 (HealthDay News) — For patients with psoriasis, survival from COVID-19 is high, with increased hospitalization risk in association with nonbiologic systemic therapy versus biologic use, according to a study published online Oct. 16 in the Journal of Allergy and Clinical Immunology.
Findings Conflicted for Benefit of Tocilizumab in COVID-19
FRIDAY, Oct. 23, 2020 (HealthDay News) — Tocilizumab may be beneficial for adults with COVID-19 admitted to the intensive care unit, although other findings are conflicting, according to three studies and an editorial published online Oct. 20 in JAMA Internal Medicine.
FDA Approves Remdesivir for Treatment of COVID-19
THURSDAY, Oct. 22, 2020 (HealthDay News) — The U.S. Food and Drug Administration has approved the first treatment for COVID-19.
CDC Broadens Definition of ‘Close Contact’ in Tracing COVID-19 Infections
THURSDAY, Oct. 22, 2020 (HealthDay News) — In a move that widens the pool of people considered at risk for COVID-19 infection, U.S. health officials released new guidance on Wednesday that redefines who is considered a “close contact” of an infected individual.
U.S. COVID-19 Vaccine Trial Enrolls 30,000
THURSDAY, Oct. 22, 2020 (HealthDay News) — The first company to start a phase 3 trial of a COVID-19 vaccine reached its target of enrolling 30,000 participants, CNN reported Thursday.
CDC: Number of COVID-19 Deaths May Be Underreported
Significant Association ID"d Between Hepatitis C, Overactive Bladder .jpg)
Study Looks at Barriers to Initiation of Rotavirus Vaccine 
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Obstructive Sleep Apnea Tied to Nearly Doubled Risk for Flu, COVID-19 in Childhood 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Physical Exams May Not Reliably Diagnose Pediatric Pneumonia .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
